167 related articles for article (PubMed ID: 10088639)
21. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
[TBL] [Abstract][Full Text] [Related]
22. Haematopoietic progenitors and signal transduction in polycythaemia vera and primary thrombocythaemia.
Kralovics R; Prchal JT
Baillieres Clin Haematol; 1998 Dec; 11(4):803-18. PubMed ID: 10640218
[TBL] [Abstract][Full Text] [Related]
23. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
Geron I; Abrahamsson AE; Barroga CF; Kavalerchik E; Gotlib J; Hood JD; Durocher J; Mak CC; Noronha G; Soll RM; Tefferi A; Kaushansky K; Jamieson CH
Cancer Cell; 2008 Apr; 13(4):321-30. PubMed ID: 18394555
[TBL] [Abstract][Full Text] [Related]
24. Lessons from familial myeloproliferative disorders.
Skoda R; Prchal JT
Semin Hematol; 2005 Oct; 42(4):266-73. PubMed ID: 16210040
[TBL] [Abstract][Full Text] [Related]
25. Imatinib effect on growth and signal transduction in polycythemia vera.
Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
[TBL] [Abstract][Full Text] [Related]
26. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB.
Dai C; Chung IJ; Krantz SB
Exp Hematol; 2005 Feb; 33(2):152-8. PubMed ID: 15676208
[TBL] [Abstract][Full Text] [Related]
27. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels.
Percy MJ; Scott LM; Erber WN; Harrison CN; Reilly JT; Jones FG; Green AR; McMullin MF
Haematologica; 2007 Dec; 92(12):1607-14. PubMed ID: 18055983
[TBL] [Abstract][Full Text] [Related]
28. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
29. T cells from patients with polycythemia vera elaborate growth factors which contribute to endogenous erythroid and megakaryocyte colony formation.
Ishii T; Zhao Y; Shi J; Sozer S; Hoffman R; Xu M
Leukemia; 2007 Dec; 21(12):2433-41. PubMed ID: 17713553
[TBL] [Abstract][Full Text] [Related]
30. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
Vainchenker W; Constantinescu SN
Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
[TBL] [Abstract][Full Text] [Related]
31. Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukin-11 and interleukin-8.
Corre-Buscail I; Pineau D; Boissinot M; Hermouet S
Exp Hematol; 2005 Nov; 33(11):1299-308. PubMed ID: 16263414
[TBL] [Abstract][Full Text] [Related]
32. Towards a molecular understanding of polycythemia rubra vera.
Pahl HL
Eur J Biochem; 2000 Jun; 267(12):3395-401. PubMed ID: 10848954
[TBL] [Abstract][Full Text] [Related]
33. Endogenous BFU-E in peripheral blood in diagnosis of polycythemia vera.
Biljanović-Paunović L; Ruvidić R; Pavlović-Kentera V
Eur J Haematol; 1990 Nov; 45(5):262-6. PubMed ID: 2261952
[TBL] [Abstract][Full Text] [Related]
34. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
35. Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice.
Akada H; Akada S; Hutchison RE; Mohi G
Haematologica; 2012 Sep; 97(9):1389-93. PubMed ID: 22371173
[TBL] [Abstract][Full Text] [Related]
36. Evolving understanding of the cellular defect in polycythemia vera: implications for its clinical diagnosis and molecular pathophysiology.
Prchal JT; Prchal JF
Blood; 1994 Jan; 83(1):1-4. PubMed ID: 8274728
[No Abstract] [Full Text] [Related]
37. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease.
Kralovics R; Stockton DW; Prchal JT
Blood; 2003 Nov; 102(10):3793-6. PubMed ID: 12829587
[TBL] [Abstract][Full Text] [Related]
38. The effects of IL-1 and IL-4 on the Epo-independent erythroid progenitor in polycythaemia vera.
de Wolf JT; Hendriks DW; Esselink MT; Halie MR; Vellenga E
Br J Haematol; 1994 Oct; 88(2):242-6. PubMed ID: 7803266
[TBL] [Abstract][Full Text] [Related]
39. Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis.
Cazzola M
Haematologica; 2007 Dec; 92(12):1585-9. PubMed ID: 18055979
[No Abstract] [Full Text] [Related]
40. Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera.
Guglielmelli P; Tozzi L; Bogani C; Iacobucci I; Ponziani V; Martinelli G; Bosi A; Vannucchi AM;
Blood; 2011 Jun; 117(25):6923-7. PubMed ID: 21527532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
